September 5, 2022Open Access

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial

Key Points

Key points are not available for this paper at this time.

Abstract

Similar efficacy for somapacitan compared to daily GH was demonstrated over 52 weeks of treatment with comparable safety and mean IGF-I SDS levels in treatment-naïve children with GHD.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Miller et al. (Mon,) studied this question.

synapsesocial.com/papers/69d7423cc74376700bf311d7 https://doi.org/https://doi.org/10.1210/clinem/dgac513

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial2020 · 64 citations
2Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 32021 · 51 citations
3Potential of liraglutide in the treatment of patients with type 2 diabetes2009 · 74 citations
4RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRIST1959 · 5,566 citations
5SUN-248 Growth Hormone Deficiency (GHD): Assessing Burden of Treatment in Children and Adolescents2019 · 1 citations

Bookmark

View Full Paper